Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

PolyPid Ltd. PYPD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • IL • USD

SharesGrow Score
56/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.50
+114.9%

PolyPid Ltd. (PYPD) is a Biotechnology company in the Healthcare sector, currently trading at $4.42. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is PYPD = $10 (+114.9% upside).

Valuation: PYPD trades at a trailing Price-to-Earnings (P/E) of -2.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.

Net income is $34M (loss), growing at +0.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $11M equity (Debt-to-Equity (D/E) ratio 0.25, conservative). Current ratio is 1.97 (strong liquidity). Debt-to-assets is 12.5%. Total assets: $22M.

Analyst outlook: 8 / 9 analysts rate PYPD as buy (89%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$9.50
▲ 114.93% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for PolyPid Ltd., the average price target is $9.50, with a high forecast of $10.00, and a low forecast of $9.00.
Highest Price Target
$10.00
Average Price Target
$9.50
Lowest Price Target
$9.00

PYPD SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 45/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PYPD

✓
VALUE Pass
100/100
PYPD trades at a trailing Price-to-Earnings (P/E) of -2.6 (S&P 500 average ~25). Forward PEG 0.07 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $10, implying +126.2% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
45/100
PYPD: +0%/yr revenue is, +0.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PYPD: Debt-to-Equity (D/E) ratio 0.25 (conservative), Current ratio is 1.97 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
PYPD: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 8 / 9 analysts rate PYPD as buy (89%). Analyst consensus target is $10 (+126.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.3-5.12
Volume128.67K
Avg Volume (30D)60.33K
Market Cap$45.04M
Beta (1Y)1.46
Share Statistics
EPS (TTM)-2.09
Shares Outstanding$16.35M
IPO Date2020-06-26
Employees57
CEODikla Czaczkes Akselbrad
Financial Highlights & Ratios
EBITDA$-31.86M
Net Income$-34.17M
Operating Income$-32.97M
Total Cash$12.93M
Total Debt$2.8M
Net Debt$-3.61M
Total Assets$22.31M
Price / Earnings (P/E)-2.1
Analyst Forecast
1Y Price Target$9.50
Target High$10.00
Target Low$9.00
Upside+114.9%
Rating ConsensusBuy
Analysts Covering9
Buy 89% Hold 11% Sell 0%
Price Target Summary
Company Info
CountryIL
ExchangeNASDAQ Global Market
CurrencyUSD
ISINIL0011326795

Price Chart

Track all markets on TradingView
PYPD
PolyPid Ltd. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
2.30 52WK RANGE 5.12

People Also View

ARMP
ARMP
Armata Pharmaceuticals, Inc.
$12.88
+10.18%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 VACC
VACC
Vaccitech plc
$5.00
+11.36%
 PYXS
PYXS
Pyxis Oncology, Inc.
$1.70
-0.58%
 ANIX
ANIX
Anixa Biosciences, Inc.
$2.88
+1.05%
 LABP
LABP
Landos Biopharma, Inc.
$22.93
+0.57%
 CUE
CUE
Cue Biopharma, Inc.
$0.44
-7.26%
 INMB
INMB
INmune Bio, Inc.
$1.26
+1.61%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message